- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05358379
A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of THT140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.
연구 개요
상세 설명
Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations.
Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:
Group 1: Bladder cancer
Group 2: Breast cancer: Triple-negative breast cancer (TNBC)
Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])
Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC)
Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC
Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL)
Group 7: T-cell lymphoma (cutaneous T-cell lymphoma [CTCL] and peripheral T-cell lymphoma [PTCL])
Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Mark H Kirschbaum, MD
- 전화번호: 626-316-3394
- 이메일: mark.kirschbaum@tethrabio.com
연구 연락처 백업
- 이름: Jason Summa
- 이메일: jason.summa@tethrabio.com
연구 장소
-
-
-
Seoul, 대한민국
- 아직 모집하지 않음
- Seoul National University Hospital
-
연락하다:
- Do-Youn Oh, Prof. MD
- 전화번호: +82-2-2072-0701
- 이메일: ohdoyoun@snu.ac.kr
-
-
-
-
New York
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
연락하다:
- Horwitz Steven, MD
- 전화번호: +1 646-608-2680
- 이메일: Horwitzs@mskcc.org
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- MD Anderson Cancer Center
-
연락하다:
- Rabia Khan
- 전화번호: +1 713-563-4667
- 이메일: RKhan@mdanderson.org
-
-
Washington
-
Seattle, Washington, 미국, 98109
- 모병
- Fred Hutchinson Cancer Center/ University of Washington
-
연락하다:
- Gentry GT King, MD
- 이메일: gking@fredhutch.org
-
-
-
-
-
Barcelona, 스페인
- 아직 모집하지 않음
- Hospital Universitario Vall d'Hebron
-
연락하다:
- Maria Vieito, MD
- 이메일: Mvieito@vhio.net
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Males or females aged ≥ 18 years.
-
Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
- For Phase 1, all tumor types may be enrolled
- For Phase 2, subjects will be enrolled as per the study design section above
-
ECOG performance status of 0-2.
-
Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease
-
Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.
-
Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
-
Able to agree to and sign the informed consent and to comply with the protocol.
Exclusion Criteria:
-
Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
-
Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-19.
-
Subjects with a history of another primary malignancy, other than:
- In situ carcinomas, e.g., breast, cervix, and prostate
- Locally excised nonmelanoma skin cancer
- No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
-
Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.
-
Diseases that significantly affect GI absorption of THT140.
-
Subjects who have impaired cardiac function or clinically significant cardiac disease.
-
Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
-
Presence of an active infection requiring intravenous antibiotics
-
Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism
-
Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.
-
Major surgery/surgical therapy for any cause within 4 weeks of the first dose
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Phase 1 Dose Escalation
Phase 1 = THT140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
다른 이름들:
|
|
실험적: Phase 2
Phase 2 = Recommended THT140 phase 2 dose and schedule administered orally in 28-day cycles. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum tolerated dose
기간: 6 months
|
The incidence rate of dose-limiting toxicities (first cycle only) at each dose level |
6 months
|
|
Overall Response Rate (ORR)
기간: 18 months
|
Assessment of response criteria according to RESIST, Lugano or mSWAT. |
18 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adverse events
기간: 24 months
|
Type, frequency, and severity of adverse drug reactions |
24 months
|
|
AUC
기간: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Cmax
기간: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Tmax
기간: 6 months
|
THT140 plasma concentrations |
6 months
|
|
T1/2
기간: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Disease Control Rate
기간: 24 months
|
To evaluate the disease control rate (DCR) in subjects receiving THT140. |
24 months
|
|
Duration of Response
기간: 24 months
|
To evaluate the duration of response (DOR) in subjects receiving THT140. |
24 months
|
|
Progression-free Survival
기간: 24 months
|
To evaluate progression-free survival (PFS) in subjects receiving THT140. |
24 months
|
|
Overall Survival
기간: 24 months
|
To evaluate overall survival (OS) in subjects receiving THT140. |
24 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pharmacodynamics
기간: 6 months
|
Pharmacodynamic response to THT140 will be assessed by mRNA sequencing of blood samples to determine differential expression of PLK1 target genes (including MYC, PLK1, CDKN1A) relative to baseline. |
6 months
|
|
Pharmacogenomics
기간: 24 months
|
Genomic alterations will be assessed by next generation sequencing (NGS) at baseline and various time points during treatment with THT140 in order to investigate the relationship between genetic alterations in THT140 related pathways and response to THT140. Parameters of genetic variations (DNA mutations) and copy number variations using plasma cell-free DNA derived from peripheral blood will be assessed. |
24 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- THT140-101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .